Stockreport

ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation [Yahoo! Finance]

ZyVersa Therapeutics, Inc.  (ZVSA) 
PDF characterized by deposition of insoluble amyloid fibrils in tissues and organs disrupting their structure and function. Extracellular ASC interacts with serum amyloid [Read more]